Navigation Links
Optherion Licenses Worldwide Rights to Develop Age-Related Macular Degeneration Diagnostics Based on Chromosome 10 Genetic Variations
Date:10/23/2007

License with University of Pittsburgh Brings Additional Key Gene Locus as a

Development Opportunity for Recently-Funded Company

NEW HAVEN, Conn., Oct. 23 /PRNewswire/ -- Optherion, Inc., a company developing products to treat and diagnose dry and wet Age-related Macular Degeneration (AMD) and other chronic diseases involving the alternative complement system, announced today that it has licensed from the University of Pittsburgh the worldwide rights to develop diagnostic products for AMD associated with specific variations in genes on Chromosome 10.

Scientists at the University of Pittsburgh published in 2005 their findings of a link between Chromosome 10, specifically the LOC387715 and HTRA1 genes, and AMD, the leading cause of blindness in people over 60 in the developed world. Genetic tests that can identify people at risk of developing AMD, or that can predict the likely rate of progression and end-stage outcome of patients already diagnosed, should enable medical professionals to intervene more aggressively at an earlier stage with lifestyle changes and available therapies, thereby changing the course of disease.

AMD is caused by degeneration of the macula, the region of the retina responsible for central vision. AMD is unique in that it is a common disease that has recently been linked to common variations in only a few specific genes, presenting opportunities to develop both diagnostic tests and disease- modifying treatments. There are 15-20 million people with AMD in the U.S. and more than 50 million worldwide.

Optherion announced on October 9 that it had completed a $37 million financing. The Company was founded following scientific discoveries published in 2005 linking the role of Complement Factor H (CFH) and Complement Factor B (CFB) -- both regulators of the alternative complement pathway - to AMD. Three gene loci have been strongly linked to AMD: CFH, CFB, and specific variations on Chromosome 10. About half of
'/>"/>

SOURCE Optherion, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. US Government Licenses New Hypertension Drug
2. Panacea Biotec In-Licenses FMD Vaccine
3. Thailand Goes Ahead With Licenses for Generic Drugs
4. Swedish Biotech Licenses HIV Drug to China for Development
5. More Foreign Trained Doctors Receive Licenses
6. FDA Licenses First US Vaccine Against Avian Flu
7. Thailand Will Not Issue Compulsory Licenses for Patented Drugs
8. Drop in Worldwide Measles deaths by 40%
9. Drugs Banned worldwide still available in India
10. Domestic Violence: The Silent Killer of Women Worldwide
11. New Study Questions Cannibalism As A Worldwide Selective Force
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2008)...Ind., Aug. 29 /PRNewswire/ -- Conseco Insurance Co...announced the availability of its new,indexed uni... The policy,provides upside potential with downsid...niversal life policy that offers the,opportunity f...m index,credit of 1%. Clients can customize their ...
(Date:8/29/2008)...Va., Aug. 29 /PRNewswire-USNewswire/ -- The Custom...d today the launch of the Endocrine,Daily Briefing...tigious,Endocrine Society., Endocrine Daily Brief...0 Endocrine Society members, medical professionals...betes and osteoporosis. Endocrine Daily,Briefing j...
(Date:8/29/2008)...ates disappointed that Obama failed to address the...- Speaking at the Democratic,National Convention W...ed,for a reinvigorated response to the domestic HI...Presidential nominee Barack Obama, Clinton said,"...ble global leadership in,an area in which I am dee...
(Date:8/29/2008)...ON, Aug. 29 /PRNewswire-USNewswire/ -- The followi...Campaign for Tobacco-Free Kids:, For the second t...d to,withdraw sponsorship and promotion of a conce...rnational criticism for engaging in cigarette,mark...p Morris International has been forced to withdraw...
Breaking Medicine News(10 mins):Health News:ConsecoLifeOptions Launched by Conseco Insurance Company as New Universal Life Product 2Health News:Custom Briefings Announces Launch of Endocrine Daily Briefing 2Health News:Bill Clinton and Other Leaders Call For 'Renewal of Battle Against AIDS' in the United States at Democratic Convention 2Health News:Bill Clinton and Other Leaders Call For 'Renewal of Battle Against AIDS' in the United States at Democratic Convention 3Health News:Philip Morris International Forced to Drop Another Concert Sponsorship; Philippines Health Department Applauded for Taking Action 2
...s suffering from tennis elbow ask them to alter th....// A new study evaluating the muscle firing patte... no bearing on the development of tendonitis. Res...p" on the relationship between the development of ...
...has made public its plan of enforcing a ban on smo...ices, cinemas, factories, pubs, bars and such othe... ban.// But the ban does not include outdoors or p...s in England will be required to put up visible “N...
...ey 2005-06 has revealed the extent of spousal viol... injustice meted out to unmarried women. The surve... f 30 organizations who were involved in accumulat...ment in certain categories. Fred Arnold, Vice-Pres...
... needed, especially into the possible genetic and ... in Bhopal exactly// 22 years ago that killed more... subsequent years. Despite the neurological, horm...he survivors are facing besides the genetic damage...
Other Medicine News:Health News:Tennis Elbow is Not Caused Due to Improperly Sized Tennis Racket Grip 2Health News:Tennis Elbow is Not Caused Due to Improperly Sized Tennis Racket Grip 3Health News:Children of Bhopal Gas Victims Suffer from Deformity 2Health News:Children of Bhopal Gas Victims Suffer from Deformity 3
(Date:8/26/2008)...wswire/ -- Semafore Pharmaceuticals Inc.,presented...geted Therapies,in Cancer in Washington, D.C., ann...se inhibitors that demonstrate significant antican... proprietary molecular scaffold has been developed...ign of pan-PI3 kinase inhibitors,as well as isofor...
(Date:8/26/2008)...nnovative Manufacturing - Has Potential to ..., ROCKVILLE, Md., Aug. 26 /PRNewswire-FirstCall/ ...favorable results from the second stage of,the Pha...uenza virus-like,particle (VLP) vaccine candidate....induced robust neutralizing antibody responses. No...
(Date:8/25/2008)... calls it a ,miracle, LATHAM, N.Y., Aug. 25 /PRN...ided Radiation Therapy program at Community Care P... patients using RapidArc(TM),radiotherapy technolo...dvancement that delivers a highly-precise image-gu...tment in two minutes or less., RapidArc treatment...
(Date:8/22/2008)...Newswire-FirstCall/ -- Human Genome,Sciences, Inc....leted the,enrollment and initial dosing of patient...umumab) in combination with the chemotherapy agent... in advanced non-small cell,lung cancer (NSCLC)., ...416/HGSLOGO ), "There is an urgent medical need ...
Breaking Medicine Technology:Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 2Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 3Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program 2Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program 3Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program 4Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program 5Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program 6Image Guided Radiation Therapy in Latham, NY. Now Fighting Cancer Using Fast and Precise RapidArc(TM) Radiotherapy Technology 2Image Guided Radiation Therapy in Latham, NY. Now Fighting Cancer Using Fast and Precise RapidArc(TM) Radiotherapy Technology 3Human Genome Sciences Completes Enrollment in Randomized Phase 2 Trial of HGS-ETR1 in Non-Small Cell Lung Cancer 2Human Genome Sciences Completes Enrollment in Randomized Phase 2 Trial of HGS-ETR1 in Non-Small Cell Lung Cancer 3Human Genome Sciences Completes Enrollment in Randomized Phase 2 Trial of HGS-ETR1 in Non-Small Cell Lung Cancer 4Human Genome Sciences Completes Enrollment in Randomized Phase 2 Trial of HGS-ETR1 in Non-Small Cell Lung Cancer 5National Stem Cell Holding in Final Stage Negotiations for Exclusive Licensing of its Recently Discovered Biomaterial for Anti Aging Applications 1501 1National Stem Cell Holding in Final Stage Negotiations for Exclusive Licensing of its Recently Discovered Biomaterial for Anti Aging Applications 1501 2Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine 28MSI 1436 29 Data from the North American Association for the Study of Obe 658 1Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine 28MSI 1436 29 Data from the North American Association for the Study of Obe 658 2Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine 28MSI 1436 29 Data from the North American Association for the Study of Obe 658 3Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine 28MSI 1436 29 Data from the North American Association for the Study of Obe 658 4Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine 28MSI 1436 29 Data from the North American Association for the Study of Obe 658 5Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine 28MSI 1436 29 Data from the North American Association for the Study of Obe 658 6Scientists discover tiny RNAs play a big role in controlling genes 4578 1Public not so sure personalized medicine 4574 1Public not so sure personalized medicine 4574 2
...serex Tango ophthalmic laser system provides two l...isruptor for posterior capsulotomy and iridotomy. ...ing pulsed 532 nm light. The photodisruptor laser ...ser can be easily selected and treatment by both l...
Thin and smooth jaws, designed to enter trough 3 mm incision, cross action.
Flat handle.
Angled shafts, smooth jaws, polished finish.
Medicine Products: